INBX
NASDAQ HealthcareInhibrx Biosciences, Inc. - Common Stock
Biotechnology
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
�� 市场数据
| 价格 | $88.23 |
|---|---|
| 成交量 | 416,342 |
| 市值 | 1.29B |
| RSI（14日） | 85.6 超买 |
| 200日均线 | $56.68 |
| 50日均线 | $73.47 |
| 52周最高 | $94.56 |
| 52周最低 | $10.84 |
| Forward P/E | -31.62 |
| Price / Book | 161.00 |
🎯 投资策略评分
INBX 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (86/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🚀 Moon Shot (2/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 INBX in your text
粘贴任何文章、记录或帖子 — 工具将提取 INBX 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.